TKTereza Kratochvílová

Tereza Kratochvílová

*This is an algorithmically generated author record based on publicly available information.

Tereza Kratochvílová has a total of 20 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Registration of a pregnant woman in the maternity hospital (optimally at 36th–37th weeks) at the Olomouc University Hospital in 2022

    by Marek Ľubušký, Veronika Durdová, Tereza Kratochvílová, Michaela Maděrková Tozzi, Kateřina Campsie, Alexandra Šinská, Eliška Hostinská, Martina Studničková, Renata Černohouzová, Martin Knápek, et al.

    Objective:The aim of the study was to analyse the results of the implementation of the new health service Registration of a pregnant woman in the maternity hospital (optimally at 36th-37th weeks) provided as part of outpatient/ ambulatory health care at Olomouc University Hospital (OUH). Materials and methods: A prospective cohort study. In 2022, a total of 2,271 women gave birth in OUH, and 2,010 of them were Registered in the maternity hospital, defined specific risks were identified and a pregnancy termination strategy was established/ determined. Results: The health service was provided to 88.5% of women giving birth (2,010/ 2,271). The age of the mothers was 15-56 years (mean 31.3 years; median 31 years), their body mass index was 13.4-53.1 kg/m2 (mean 24.6 kg/ m2; median 23.2 kg/ m2). 43.6% of them (877/ 2,010) were Low-risk pregnancies and 56.4% (1,133/ 2,010) were Pregnancies with a defined specific risk. The most frequently identified risks were as follows: RhD negative blood group (18.4%), diabetes mellitus (13.9%), history of caesarean section (12.0%), hypertensive disorders (6.5%), small fetus/ fetal growth restriction (6.3%), risk the development of hemolytic disease in the fetus and the newborn (2.5%), multiple pregnancy (1.6%), congenital malformation of the fetus (1.3%) and placentation disorders (0.5%). In 63.4% of them (1,275/ 2,010), the pregnancy termination strategy was determined by spontaneous vaginal delivery, in 18.0% (361/ 2,010) by pre-induction of vaginal delivery and in 14.2% (285/ 2,010) by caesarean section. In 4.4% (89/ 2,010) the health service was not implemented correctly because no strategy was established. Conclusion: The implementation of the new health service will make it possible to replace activity (more frequent antenatal care contacts/ visits and routine antenatal cardiotocography) with efficiency (risk identification, determination of the optimal strategy for outpatient/ ambulatory antenatal care and timing and mode of delivery) and thereby provide better and safer health care (from a medical, organizational, legislative and economic points of view).

    • 1 December 2015
      • Vol. 80  (6) , 401-4

    [Spontaneous antepartal RhD alloimmunization].

    by M Studničková, I Holusková, V Durdová, T Kratochvílová, P Strašilová, I Marková, M Lubušký

    Assess the incidence of spontaneous antepartal RhD alloimmunization in RhD negative pregnant women with an RhD positive fetus. Clinical study. Department of Obstetrics and Gynecology, Medical School and University Hospital Olomouc. A total of 906 RhD negative women with an RhD positive fetus and without the presence of anti-Dalloantibodies at the beginning of pregnancy were examined. Always it was a singleton pregnancy, RhD blood group of the pregnant women was assessed in the 1st trimester of pregnancy, RhD status of the fetus was determined after delivery. Screening for irregular antierythrocyte antibodies was performed in all women in the 1st trimester of pregnancy, at 28-32 weeks gestation and immediately prior to delivery at 38-42 weeks gestation. Screening for irregular antierythrocyte antibodies was performed also at 6 months following delivery in all cases of positive antibodies before delivery. Antibody screening was performed using the indirect antiglobulin (LISS/NAT) and enzyme (papain) test with their subsequent identification using a panel of reference erythrocytes by column agglutination method Dia-Med. After delivery, the volume of fetomaternal hemorrhage was assesed in all RhD negative women and RhD alloimmunization prophylaxis was performed by administering the necessary IgG anti-D dose; none of the women were administered IgG anti-D antepartally. During screening for irregular antierythrocyte antibodies at 28-32 weeks gestation, anti-D alloantibodies were diagnosed in 0.2% of the women (2/906); immediately prior to the delivery at 38-42 weeks gestation, anti-D alloantibodies were diagnosed in 2.3% of the women (21/906) and repeatedly even at 6 months following delivery (21/157). In 82.7% of the women (749/906), examination at 6 months following delivery was not performed, therefore in these women spontaneous antepartal RhD alloimmunization cannot reliably be ruled out. Alloimmunization may not be diagnosed yet at term of delivery. If anti-D alloantibodies were not present prior to the delivery, these women were all administered IgG anti-D in a dose of at least 125 μg after delivery. In RhD negative women with an RhD positive fetus, the incidence of spontaneous antepartal RhD alloimmunization was at least 2.3%. Most cases may theoretically be prevented by prophylactic administration of 250 μg of IgG anti-D to all RhD negative women at 28 weeks gestation.